Laurus Labs Ltd (LAURUSLABS)
₹2,405.50
Mkt cap
₹1.30L Cr
P/E ratio
97.00
P/B
21.48
Div yield
0.08%
ROE
18.30%
ROCE
17.80%
EPS (TTM)
₹24.80
Book value
₹112
52W range
902–2,406
Sector
Healthcare
Price history
Previous close
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]
NSE LAURUSLABSBSE 540222
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
0.00% from high₹2,406
₹902+166.58% from low₹2,406
Current
₹2,405.50
Prev close
₹2,244.00
Day
+7.20%
Price performance
1D
+7.20%
1W
+22.11%
1M
+21.55%
3M
+35.04%
6M
+117.48%
1Y
+157.44%
YTD
+117.40%
Financials
Revenue, profit & margin
P/E ratio
97.0×
LAURUSLABS is 182% above the sector median of 34.4×
LAURUSLABS97.0×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,224 | 1,195 | 1,440 | 1,195 | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 | 2,206 | |
| Expenses | 1,037 | 1,014 | 1,198 | 1,024 | 1,045 | 1,130 | 1,300 | 1,187 | 1,250 | 1,298 | 1,299 | 1,388 | 1,456 | |
| Operating Profit | 188 | 181 | 241 | 171 | 178 | 285 | 421 | 382 | 403 | 480 | 512 | 638 | 750 | |
| OPM % | 15% | 15% | 17% | 14% | 15% | 20% | 24% | 24% | 24% | 27% | 28% | 32% | 34% | |
| Other Income | 2 | 2 | 19 | 3 | 5 | 9 | 59 | 10 | 27 | 6 | 12 | 9 | 13 | |
| Interest | 42 | 51 | 50 | 49 | 53 | 58 | 56 | 52 | 40 | 39 | 40 | 42 | 44 | |
| Depreciation | 93 | 98 | 102 | 106 | 108 | 106 | 110 | 117 | 120 | 121 | 122 | 124 | 127 | |
| Profit before tax | 54 | 35 | 107 | 18 | 23 | 131 | 312 | 224 | 270 | 327 | 361 | 481 | 592 | |
| Tax % | 27% | 27% | 30% | 34% | 22% | 31% | 25% | 28% | 28% | 22% | 22% | 25% | 26% | |
| Net Profit | 37 | 23 | 75 | 13 | 20 | 93 | 233 | 162 | 194 | 252 | 282 | 362 | 436 | |
| EPS in Rs | 0.69 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 | 4.33 | 3.02 | 3.61 | 4.66 | 5.17 | 6.80 | 8.17 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.32% · closed higher next day 22 of last 43
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26† | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 24 Jan '24◦ | 25 Apr '24◦ | 25 Jul '24◦ | 24 Oct '24◦ | 24 Jan '25◦ | 25 Apr '25 | 25 Jul '25 | 23 Oct '25 | 23 Jan '26 | 30 Apr '26 | 24 Jul '26 | 29 Oct '26 |
| Earnings day | −5.51% | +2.59% | +3.50% | +4.14% | −11.28% | −3.08% | +0.15% | +1.49% | +1.05% | −0.47% | +2.10% | +7.20% |
| +1 day | −6.66% | +4.19% | +3.95% | +10.04% | −15.25% | −2.94% | +6.31% | +0.62% | −0.56% | +5.45% | +9.25% | — |
| +5 days | −2.07% | +3.12% | +3.05% | +8.98% | −1.17% | −4.29% | +1.54% | +5.40% | −5.16% | +11.05% | +15.81% | — |
| +15 days | −0.26% | +4.40% | +0.65% | +9.32% | −9.37% | −5.91% | +3.48% | +8.51% | +0.66% | +21.46% | +13.96% | — |
| +30 days | +2.23% | +4.17% | +13.16% | +28.05% | −7.24% | +3.38% | +7.87% | +11.45% | +3.20% | +25.59% | +17.32% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Interim Dividend - Re 1 Per Share | — | 6 Nov '26 | 6 Nov '26 |
| dividend Interim Dividend - Rs 1.20 Per Share | 1.20 | 8 May '26 | 8 May '26 |
Shareholding
as of Sep 202627.47%Promoter
Promoters27.47%
FIIs30.84%2.84
DIIs11.86%1.87
Public29.85%0.94
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports13
Concall transcripts97
PPTOct 2026RECOct 2026PPTSep 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptOct 2025PPTOct 2025RECOct 2025PPTSep 2025TranscriptJul 2025PPTJul 2025TranscriptApr 2025PPTApr 2025RECApr 2025TranscriptJan 2025PPTJan 2025PPTJan 2025
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 OctAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 29 Oct - Q2 FY27 results conference call audio recording hosted on October 29, 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 29 Oct - Laurus Labs reported H1 FY27 revenue of ₹4,233 Cr and agreed to acquire 60% of Galenvs Sciences on 29 Oct 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 29 OctCorporate Action-Board approves Dividend 29 Oct